A patient-centered look at where cancer-related financial pressure is highest, how direct and indirect costs reach household decisions, and what patients say could make care more affordable and manageable.
Audience: Cancer Care Patients
Countries: 5
Completion Rate: 68.7%
SGID: 8979573
-Hero findings
– Quick Read — Key Findings
Cancer care can bring several financial pressures at the same time: medicines, hospital care, tests, insurance cost-sharing, travel, time away from work, and the everyday household expenses that continue while treatment is underway.
The idea is often called financial toxicity: the National Cancer Institute uses the term for financial problems related to the cost of medical care and notes cancer treatment can affect a person’s ability to work and pay bills, while the World Health Organization frames financial protection as obtaining needed care without health spending compromising basic needs.
The MDForLives survey gives that issue a patient-level shape across five countries, asking not only whether care is expensive but when pressure is highest, which costs are hardest, whether financial strain changes treatment or follow-up, how households cope, and what support patients believe would help most.
51.4% say cancer-related financial pressure peaks during active treatment. Long-term or maintenance care follows at 27.8%, while 16.7% point to diagnosis and initial testing.
That timing matters because active treatment is when many direct and indirect costs arrive together, medicines, hospital visits, repeated appointments, travel, time away from work, and insurance cost-sharing, and cancer medicines stand out as the single largest direct burden here at 47.9%.
33.3% identify high out-of-pocket costs as the payment challenge creating the greatest financial pressure. Deductibles or copays follow at 29.2%, and non-covered treatments or medicines at 27.8%.
The pattern shows why a patient can have coverage and still feel financially exposed: insurance can reduce the total price of care without removing the amount due at each prescription, procedure, visit, or new coverage period, and in systems with broader public coverage the pressure may shift toward income loss, travel, or costs outside the formal benefit package.
23.6% say cancer-related cost pressure delayed treatment, another 23.6% say it led to missed medicines or follow-ups, and 20.8% say they changed treatment or provider.
The National Cancer Institute describes cost-related medication nonadherence as one consequence of financial toxicity, and the MDForLives data broaden the picture, cost can also affect appointments, treatment timing, and provider choices, though 31.9% report no major treatment change, an important counterpoint.
54.3% say lost income or employment is the indirect cost affecting their household most. Travel and accommodation follows at 18.6%, caregiver expenses at 15.7%, and household or childcare costs at 11.4%.
37.1% say patient financial assistance would improve their cancer-care experience most, while 34.3% choose broader insurance coverage. When asked what would make care more affordable, 38.6% prioritize better insurance reimbursement.
The affordability question points the same way: better insurance reimbursement leads at 38.6%, followed by lower medicine and treatment costs at 30.0% and expanded financial-assistance programs at 28.6%, with greater cost transparency chosen by only 2.9% as the single change that would most help. That does not make transparency unimportant, several open responses ask for clearer cost information and describe the time spent talking to insurers and arranging payment plans, but information alone does not solve the problem if the amount owed still exceeds what a household can afford.
The survey’s central tension is that cancer-related financial pressure is both medical and non-medical: medicines are the leading direct expense, but lost income or employment is the largest indirect burden, and active treatment is when pressure most often peaks, while savings, family support, financial assistance, and borrowing become ways to keep care moving.
The most consequential finding is not simply that cancer is expensive, but that cost reaches care decisions for some patients, delayed treatment, missed medicines or follow-ups, and treatment or provider changes all appear in the data, while others report no major change, variation that reflects different coverage, income, support networks, and health-system protections.
You have read the summary
Direct answers to common questions around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
